VIVUS, Nordmark revise contract agreement for PANCREAZE development
Category: #health  By Paroma Bhattacharya  Date: 2019-06-28
  • share
  • Twitter
  • Facebook
  • LinkedIn

VIVUS, Nordmark revise contract agreement for PANCREAZE development

California-headquartered biopharmaceutical firm VIVUS Inc. has recently announced an amendment to its contract manufacturing and supply agreement of delayed release capsules PANCREAZE® with Nordmark Arzneimittel GmbH & Co. KG.

Apparently, the revised treaty covers an initial term of 10 years followed by a renewal of additional five years. Financial terms of the agreement remained undisclosed.

Citing reliable sources, VIVUS and Nordmark will work together under the terms of the agreement to develop an advanced formulation of PANCREAZE, which is expected to enter the market by 2021, with the prime goal of extending its shelf life.

John Amos, Chief Executive Officer, VIVUS, was quoted saying that ensuring the supply of PANCREAZE to meet current and future demands of the drug at a predictable and stable price was their key strategy. He further added that with their current product formulations, there lies a bright future for PACREAZE market to create additional commercial and clinical value with the introduction of the product’s advanced formulations.

Nordmark CEO Jörn Tonne stated that their firm has managed to achieve considerable expertise in manufacturing PANCREAZE, and they look forward to extending their agreement with VIVUS. He also mentioned that they have had a successful record in developing new products to meet customer needs as well as the patients they serve.

Tonne noted that Nordmark plans to work with VIVUS in developing advanced formulations of PANCREAZE that make the drug even more convenient for patients diagnosed with exocrine pancreatic insufficiency.

For the record, PANCREAZE is a prescription drug used for treatment of patients who have difficulty digesting food normally because their pancreas, due to cystic fibrosis or other conditions, is unable to produce enough enzymes. PANCREAZE contains a mixture of digestive enzymes including amylases, proteases and lipases from pig pancreas, that helps body use up proteins, sugars and fats from food. The drug is effective and completely safe in children when taken in prescribed doses.

 

Source credit: https://www.nasdaq.com/press-release/vivus-and-nordmark-amend-contract-manufacturing-agreement-to-supply-current-and-future-demand-for-20190626-00835



About Author

Paroma Bhattacharya

Email: [email protected]   

Paroma Bhattacharya

Paroma currently works as a content developer for Algosonline, MSF and a series of alike platforms. Fortified with a post-graduation degree in Journalism and Mass Communication, she delved head long into a writing career, creating resourceful and information enriched ...

Read More

More News By Paroma Bhattacharya

Walmart to roll out Delivery Unlimited grocery service across U.S.
Walmart to roll out Delivery Unlimited grocery service across U.S.
By Paroma Bhattacharya

Walmart, the retail giant, recently announced that it is rolling out a new Delivery Unlimited grocery service in 1,400 Walmart stores across U.S. Reportedly, the subscription membership will charge an annual fee of USD...

Amazon gears up for Diwali sale, expands next-day delivery service
Amazon gears up for Diwali sale, expands next-day delivery service
By Paroma Bhattacharya

The firm has increased its overall reach for large appliances to 14,000 pin codes and next-day delivery facilities to over 650 cities.

Amazon.in, the Indian divisio...

4BIO Capital intends to take gene and cell therapies mainstream
4BIO Capital intends to take gene and cell therapies mainstream
By Paroma Bhattacharya

The venture capitalist firm has secured an investment of $50 million and is expecting to gather an investment of up to $150 million till 2020.

4BIO Capital, a Londo...